Ocugen, Inc.
US ˙ NasdaqCM ˙ US67577C1053

Introduction

This page provides a comprehensive analysis of the known insider trading history of Ramesh Kumar. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Ramesh Kumar has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:OCGN / Ocugen, Inc. Director 0
US:ONTX / Onconova Therapeutics, Inc. Chief Executive Officer, Director 1,065,600
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Ramesh Kumar. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases OCGN / Ocugen, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in OCGN / Ocugen, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OCGN / Ocugen, Inc. Insider Trades
Insider Sales OCGN / Ocugen, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in OCGN / Ocugen, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OCGN / Ocugen, Inc. Insider Trades
Insider Purchases TRAW / Traws Pharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in OCGN / Ocugen, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-04-26 ONTX Kumar Ramesh 23,810 2.1000 1,299 38.5000 50,001 169 603 732,693 1,465.36
2013-11-15 ONTX Kumar Ramesh 1,100 12.0200 68 195.3250 13,222
2013-07-30 ONTX Kumar Ramesh 6,667 15.0000 410 243.7500 100,005

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRAW / Traws Pharma, Inc. Insider Trades
Insider Sales TRAW / Traws Pharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in OCGN / Ocugen, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRAW / Traws Pharma, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Ramesh Kumar as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-10-07 2022-10-06 4 OCGN Ocugen, Inc.
Common Stock
S - Sale X -4,500 0 -100.00 1.83 -8,235
2022-10-07 2022-10-06 4 OCGN Ocugen, Inc.
Common Stock
M - Exercise 4,500 4,500 0.51 2,295 2,295
2022-07-20 2022-07-18 4 OCGN Ocugen, Inc.
Common Stock
S - Sale X -7,500 0 -100.00 2.57 -19,275
2022-07-20 2022-07-18 4 OCGN Ocugen, Inc.
Common Stock
M - Exercise 7,500 7,500 0.51 3,825 3,825
2022-04-20 2022-04-18 4 OCGN Ocugen, Inc.
Option (Right to Buy)
M - Exercise 7,500 16,500 83.33
2022-04-20 2022-04-18 4 OCGN Ocugen, Inc.
Common Stock
S - Sale X -7,500 0 -100.00 2.83 -21,225
2022-04-20 2022-04-18 4 OCGN Ocugen, Inc.
Common Stock
M - Exercise 7,500 7,500 0.51 3,825 3,825
2022-01-20 2022-01-18 4 OCGN Ocugen, Inc.
Option (Right to Buy)
M - Exercise 7,500 24,000 45.45
2022-01-20 2022-01-18 4 OCGN Ocugen, Inc.
Common Stock
S - Sale X -7,500 0 -100.00 4.07 -30,525
2022-01-20 2022-01-18 4 OCGN Ocugen, Inc.
Common Stock
M - Exercise 7,500 7,500 0.51 3,825 3,825
2021-12-17 2021-12-16 4 OCGN Ocugen, Inc.
Option (Right to Buy)
A - Award 16,335 16,335
2021-10-20 2021-10-18 4 OCGN Ocugen, Inc.
Option (Right to Buy)
M - Exercise -7,500 31,500 -19.23
2021-10-20 2021-10-18 4 OCGN Ocugen, Inc.
Common Stock
S - Sale X -7,500 0 -100.00 8.13 -60,975
2021-10-20 2021-10-18 4 OCGN Ocugen, Inc.
Common Stock
M - Exercise 7,500 7,500 0.51 3,825 3,825
2021-07-21 2021-07-19 4 OCGN Ocugen, Inc.
Option (Right to Buy)
M - Exercise -7,500 39,000 -16.13
2021-07-21 2021-07-19 4 OCGN Ocugen, Inc.
Common Stock
S - Sale X -7,500 0 -100.00 6.40 -48,000
2021-07-21 2021-07-19 4 OCGN Ocugen, Inc.
Common Stock
M - Exercise 7,500 7,500 0.51 3,825 3,825
2021-04-21 2021-04-19 4 OCGN Ocugen, Inc.
Option (Right to Buy)
M - Exercise -7,500 46,500 -13.89
2021-04-21 2021-04-19 4 OCGN Ocugen, Inc.
Common Stock
S - Sale X -7,500 0 -100.00 5.33 -39,975
2021-04-21 2021-04-19 4 OCGN Ocugen, Inc.
Common Stock
M - Exercise 7,500 7,500 0.51 3,825 3,825
2021-01-04 2021-01-01 4 OCGN Ocugen, Inc.
Option (Right to Buy)
A - Award 126,000 126,000
2020-01-03 2020-01-02 4 OCGN Ocugen, Inc.
Options (Right to Buy)
A - Award 54,000 54,000
2018-07-30 2018-07-26 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 1,065,600 1,065,600
2018-02-27 2018-02-23 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 73,220 73,220
2018-01-05 2018-01-03 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 64,885 64,885
2017-04-28 2017-04-26 4 ONTX Onconova Therapeutics, Inc.
Common Stock
P - Purchase 23,810 102,227 30.36 2.10 50,001 214,677
2017-01-19 2017-01-17 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 44,027 44,027
2016-12-19 2016-12-15 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 12,673 12,673
2016-09-01 2016-09-01 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 44,000 44,000
2016-08-10 2016-07-29 4 ONTX Onconova Therapeutics, Inc.
Warrants (right to buy)
X - Other 38,071 38,071
2016-08-10 2016-07-29 4 ONTX Onconova Therapeutics, Inc.
Common Stock
X - Other 50,765 78,417 183.59 4.10 208,136 321,510
2016-08-10 2016-07-26 4 ONTX Onconova Therapeutics, Inc.
Subscription Right (right to buy)
X - Other -41,475 0 -100.00
2016-01-28 2016-01-26 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
A - Award 146,440 146,440
2015-10-01 2015-09-25 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 87,500 87,500
2015-04-20 2015-04-16 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
A - Award 87,500 87,500
2014-12-22 2014-12-18 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 175,000 175,000
2014-02-11 2014-02-10 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise X -20,000 16,739 -54.44
2014-02-11 2014-02-10 4 ONTX Onconova Therapeutics, Inc.
Common Stock
S - Sale X -20,000 276,500 -6.75 15.11 -302,200 4,177,915
2014-02-11 2014-02-10 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise X 20,000 296,500 7.23 6.00 120,000 1,779,000
2014-02-11 2014-02-07 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise X -13,543 36,739 -26.93
2014-02-11 2014-02-07 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise X 13,543 290,043 4.90 6.00 81,258 1,740,258
2014-02-11 2013-02-07 4 ONTX Onconova Therapeutics, Inc.
Common Stock
S - Sale X -13,543 276,500 -4.67 15.02 -203,416 4,153,030
2014-02-03 2014-02-03 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise X -20,000 50,282 -28.46
2014-02-03 2014-02-03 4 ONTX Onconova Therapeutics, Inc.
Common Stock
S - Sale X -20,000 276,500 -6.75 15.07 -301,400 4,166,855
2014-02-03 2014-02-03 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise X 20,000 296,500 7.23 6.00 120,000 1,779,000
2014-02-03 2014-01-31 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise X -20,000 70,282 -22.15
2014-02-03 2014-01-31 4 ONTX Onconova Therapeutics, Inc.
Common Stock
S - Sale X -20,000 276,500 -6.75 15.03 -300,600 4,155,795
2014-02-03 2014-01-31 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise X 20,000 296,500 7.23 6.00 120,000 1,779,000
2014-02-03 2014-01-30 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise X -14,744 90,282 -14.04
2014-02-03 2014-01-30 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise X -5,256 0 -100.00
2014-02-03 2014-01-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
S - Sale X -20,000 276,500 -6.75 15.05 -301,000 4,161,325
2014-02-03 2014-01-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise X 14,744 296,500 5.23 6.00 88,464 1,779,000
2014-02-03 2014-01-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
M - Exercise X 5,256 281,756 1.90 2.67 14,034 752,289
2013-12-24 2013-12-20 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 135,000 135,000
2013-11-18 2013-11-15 4 ONTX Onconova Therapeutics, Inc.
Common Stock
P - Purchase 1,100 276,500 0.40 12.02 13,222 3,323,530
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series I Convertible Preferred Stock
C - Conversion -100 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series F Convertible Preferred Stock
C - Conversion -500 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series H COnvertible Preferred Stock
C - Conversion -500 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series G Convertible Preferred Stock
C - Conversion -765 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series E Covertible Preferred Stock
C - Conversion -1,084 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series D Convertible Preferred Stock
C - Conversion -2,209 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series C Convertible Preferred Stock
C - Conversion -983 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -20,645 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -4,667 0 -100.00
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
P - Purchase 6,667 275,400 2.48 15.00 100,005 4,131,000
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 75 268,733 0.03
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 375 268,658 0.14
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 573 268,283 0.21
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 385 267,710 0.14
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 811 267,325 0.30
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 1,657 266,514 0.63
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 737 264,857 0.28
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 17,424 264,120 7.06
2013-08-01 2013-07-30 4 ONTX Onconova Therapeutics, Inc.
Common Stock
C - Conversion 3,748 246,696 1.54
2013-07-29 2013-07-25 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 100,000 100,000
2013-07-29 2013-07-25 4 ONTX Onconova Therapeutics, Inc.
Stock Option (right to purchase)
A - Award 5,000 5,000
2013-07-24 3 ONTX Onconova Therapeutics, Inc.
Common Stock
92,911
2013-07-24 3 ONTX Onconova Therapeutics, Inc.
Common Stock
150,037
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)